Compare GNLX & HYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNLX | HYNE |
|---|---|---|
| Founded | 2001 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 116.5M |
| IPO Year | 2022 | N/A |
| Metric | GNLX | HYNE |
|---|---|---|
| Price | $2.88 | $15.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 152.2K | 14.9K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.29 | $13.56 |
| 52 Week High | $8.54 | $16.14 |
| Indicator | GNLX | HYNE |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 53.69 |
| Support Level | $2.36 | $15.49 |
| Resistance Level | $2.97 | N/A |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 52.64 | 31.37 |
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.